Chemotherapy of multiple myeloma: Melphalan—40 years old and still going strong
Open Access
- 1 January 2003
- journal article
- editorial
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 9 (1) , 2-3
- https://doi.org/10.1053/bbmt.2003.50001
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: An evidence-based reviewTransplantation and Cellular Therapy, 2003
- Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapyBlood, 2002
- Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapyBlood, 2001
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple MyelomaNew England Journal of Medicine, 1996
- Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials.Journal of Clinical Oncology, 1992